In the largest study done with Exenatide  which lasted 84 weeks  scientific researchers demonstrated that using a weekly dose of Exenatide (EQW)  achieved a better glycemic control  sustained body weight loss and a reduction in the risk of hypoglycemic episodes  than daily administrations of glargine insulin